Ep190: Neil Kumar on Building a Rare Disease Drug Company
The Long Run with Luke Timmerman
00:00
Recent pivotal readouts: LGMD2I and ADH1
Neil details strong results in LGMD2I (glycosylation, CK reduction, function) and ADH1 (calcium normalization).
Play episode from 01:00:06
Transcript
